牛生长激素结构不均一性的研究

本文报导用常规方法分离纯化的牛生长激素,在还原性SDS-11％聚丙烯酰胺凝胶电泳中呈分子量很接近的两条主带(22KD,21.5KD)。用单克隆抗体和多克隆抗体亲和层析技术分析了不同分子量形式的牛生长激素的转化,结果表明:牛生长激素可能在pH5.5条件下转化为21.5KD分子,在pH8.3条件下则转化18KD分子。这几种形式的牛生长激素均保留与抗体的结合力,但亲和力不尽相同,如在亲和层析的洗脱性质上存在差异。已检验分离并部分纯化了18KD分子以备作进一步的研究。     

等电聚焦

蛋白质分子是带有电荷的两性生物高分子,其正、负电荷的数量是随分子所在环境的酸碱度而变化的。在电场存在下的一定pH缓冲液中,带正电荷的蛋白质分子将向负极移动;带负电荷的蛋白质分子将向正极移动,这就是电泳过程。在某一pH下,蛋白质分子在电场中     

人红细胞膜带3蛋白的提纯与鉴定

提出了一种分离纯化人红细胞膜带3蛋白的不含血型糖蛋白制剂的改良方法:先后用0.89％NaCl、20mM pH8.0磷酸钠和0.05％TritonX-100处理膜除去膜骨骼蛋白类和血型糖蛋白,再用自行设计的凝胶制备电泳装置进一步纯化。冰冻干燥的制剂是均质的,得率为18.5±2.85％,它的分子量、氨基酸组成和紫外吸收光谱与文献报道基本相同。     

超滤膜分离纯化加纳籽中5-羟基色氨酸的研究

研究了超滤膜从加纳籽中分离纯化5-羟基色氨酸的相关膜工艺条件及参数,并筛选出适合的聚砜超滤膜。研究结果表明,截留分子量为50 K的超滤膜分离纯化5-羟基色氨酸的效果要优于截留分子量分别为10 K和100 K的超滤膜。超滤膜分离纯化5-羟基色氨酸优化工艺条件:操作压力0.10 MPa、操作温度35℃、料液质量浓度1.141 mg/m L、p H值7.0,在此条件下5-羟基色氨酸转移率为83.5%,纯度可达90.5%。     

超滤膜分离纯化加纳籽中5-羟基色氨酸的研究北大核心CSCD

研究了超滤膜从加纳籽中分离纯化5-羟基色氨酸的相关膜工艺条件及参数,并筛选出适合的聚砜超滤膜。研究结果表明,截留分子量为50 K的超滤膜分离纯化5-羟基色氨酸的效果要优于截留分子量分别为10 K和100 K的超滤膜。超滤膜分离纯化5-羟基色氨酸优化工艺条件:操作压力0.10 MPa、操作温度35℃、料液质量浓度1.141 mg/m L、p H值7.0,在此条件下5-羟基色氨酸转移率为83.5%,纯度可达90.5%。     

Anti-IgE单链抗体纯化工艺研究及活性鉴定

目的:建立anti-IgE单链抗体纯化工艺并对其活性进行鉴定。方法:根据protein L亲和层析填料和Ni亲和层析填料的特点分析,经初筛后选用protein L填料作为第一步初纯化填料,Ni亲和层析填料作为第二步精细纯化填料。通过对这两种纯化方式的上样条件和洗脱条件进行研究,建立了anti-IgE单链抗体的纯化工艺。结果:protein L亲和层析的初纯化工艺:最佳杂质洗涤pH=3.5,最佳目标蛋白洗脱pH=2.0,并且pH=2.0洗脱的目标蛋白收集在第二步Ni亲和层析的上样缓冲液中,可直接进行第二步Ni亲和层析纯化。所建立的Ni亲和层析精细纯化工艺:最佳杂质洗涤为50mmol/L咪唑,最佳目标蛋白洗脱为500mmol/L咪唑。经两步亲和纯化,目标产物在SDS-PAGE上纯度为99.0%,CE-SDS上纯度为99.5%,两步总收率为80.0%。纯化后的蛋白经竞争ELISA和Biacore检测,证实该产品特异性识别IgE靶标,与IgE靶标的亲和力达到8.59e~(-9)M,并且竞争Biacore结果显示该抗体对IgE有良好的中和活性,其抑制IgE的EC50值为70n M。结论:建立了一种高效、简洁的大肠杆菌表达的anti-IgE单链抗体纯化工艺,为其进一步规模放大工艺的建立奠定了基础。同时证明了该新型小分子anti-IgE抗体对靶标具有良好的特异性、亲和力以及中和活性,并展示出其在医用中的应用价值。所建立的小分子抗体纯化工艺技术对其他小分子单链抗体的纯化具有参考价值。     

重组人小分子抗体ScFv-Fc发酵条件的优化及纯化

目的：研究重组人小分子抗体ScFv—Fc在毕赤酵母中分泌表达的最佳条件,以及ScFv—Fc的纯化方法。方法：分别从甲醇浓度、pH、诱导时间等方面对毕赤酵母重组菌株产生ScFv-Fc的发酵过程进行了优化;通过硫酸铵沉淀结合proteinA亲和层析柱,对ScFv—Fc的纯化方法进行了研究。结果：确定ScFv—Fc在毕赤酵母中分泌表达的最佳条件为：在pH5．2的条件下,以0．5％甲醇诱导72h。经过proteinA亲和层析柱纯化后,ScFv—Fc纯度可达94％以上。结论：确定了ScFv-Fe在毕赤酵母中分泌表达的最佳条件以及纯化方法,为重组抗体分子诊断、治疗试剂的开发以及抗体的人源化奠定了物质基础。     

高浓度氯苯优势降解菌的筛选及其降解酶的纯化

[目的]分离纯化出一株高浓度氯苯优势降解菌株,对其所产氯苯降解酶进行分离与纯化,为该菌株及其氯苯降解酶的研究提供理论参考.[方法]利用梯度富集培养技术和无菌滤纸片平板法分离菌株,通过形态特征及16S rRNA基因序列分析初步鉴定菌株,用气相色谱法测定培养液中氯苯浓度,以单位细胞氯苯降解率评价菌株对氯苯的降解能力,以氯苯降解率表示氯苯降解酶的活性.取纯化菌株的发酵酶液制备粗酶液,经硫酸铵梯度盐析、透析脱盐、DE-52离子交换层析、G-100凝胶层析和透析浓缩后,进行SDS-PAGE凝胶电泳检验酶的纯度并测定酶的分子量.[结果]从氯苯长期驯化的成熟期活性污泥中筛选到一株以氯苯为唯一碳源和能源的氯苯优势降解细菌LW13,该菌株在以2000 mg/L氯苯为唯一碳源的无机盐培养基中仍能正常生长,其单位细胞氯苯降解率可达1.37 ×10-10.扫描电镜观察到该菌株细胞大小约为2.3 ×0.8μm,长有数根端生鞭毛.16S rRNA基因序列相似性比较表明该菌株与Lysinibacillus fusiformis(溶藻菌)的相似性达95.5％.所纯化的氯苯降解酶为胞外酶,带正电荷,其分子大小约为57 kDa.整个纯化过程中酶纯化倍数化达8.0倍,酶活回收率达52.51％,酶量回收率达6.57％.纯化后的氯苯降解酶在30℃-55℃和pH在6.0-8.0之间都保持较高的酶活性,其最适反应温度和pH分别在40℃和pH8.0左右.[结论]所分离的氯苯优势降解菌属于Lysinibacillus属菌株,该菌株能有效降解高浓度(500-2000 mg/L)氯苯废水,通过逐级分离纯化,可获得氯苯降解酶纯酶,纯化指标符合分离纯化基本规律,纯化效果较为理想.     

一种新的核糖核酸酶-栝楼核糖核酸酶的纯化

从一种高等植物栝楼中分离出一种新的单一碱基特异性核楼核酸内切酶—栝楼核糖核酸酶(RNase TCS),它在pH 3.57M脲的变性条件下,能单一地把RNA分子中尿嘧啶核苷酸的5′端切开,纯化酶在SDS-PAGE中呈单一泳带,分子量为24.2KD,最大吸收峰279nm,比活12800U/mg。     

聚酰胺树脂纯化竹壳类黄酮工艺的研究

采用聚酰胺吸附树脂对竹笋壳黄酮类化合物分离纯化,确定了聚酰胺吸附树脂对竹笋壳黄酮分离纯化的最佳工艺条件:制备5mg/mL的竹笋壳黄酮提取液90mL,调节pH=5,用1.8mL/min的流速上样后,用160mL的去离子水冲洗大量杂质,随后用120mL的60%乙醇溶液洗脱120mL。在此条件下,竹笋壳黄酮的纯度为58.4%,与大孔树脂纯化方法相比,该方法更具有良好的分离纯化效果。     

Using precipitation by polyamines as an alternative to chromatographic separation in antibody purification processes

Polyamine precipitation conditions for removing host cell protein impurities from the cell culture fluid containing monoclonal antibody were studied. We examined the impact of polyamine concentration, size, structure, cell culture fluid pH and ionic strength. A 96-well microtiter plate based high throughput screening method was developed and used for evaluating different polyamines. Polyallylamine, polyvinylamine, branched polyethyleneimine and poly(dimethylamine-co-epichlorohydrin-ethylenediamine) were identified as efficient precipitants in removing host cell protein impurities. Leveraging from the screening results, we incorporated a polyamine precipitation step into a monoclonal antibody purification process to replace the Protein A chromatography step. The optimization of the overall purification process was performed by taking the mechanisms of both precipitation and chromatographic separation into account. The precipitation-containing process removed a similar amount of process-related impurities, including host cell proteins, DNA, insulin and gentamicin and maintained similar product quality in respect of size and charge variants to chromatography based purification. Overall recovery yield was comparable to the typical Protein A affinity chromatography based antibody purification process.     

Use of proteomics for validation of the isolation process of clotting factor IX from human plasma

The use of proteomic techniques in the monitoring of different production steps of plasma-derived clotting factor IX (pd F IX) was demonstrated. The first step, solid-phase extraction with a weak anion-exchange resin, fractionates the bulk of human serum albumin (HSA), immunoglobulin G, and other non-binding proteins from F IX. The proteins that strongly bind to the anion-exchange resin are eluted by higher salt concentrations. In the second step, anion-exchange chromatography, residual HSA, some proteases and other contaminating proteins are separated. In the last chromatographic step, affinity chromatography with immobilized heparin, the majority of the residual impurities are removed. However, some contaminating proteins still remain in the eluate from the affinity column. The next step in the production process, virus filtration, is also an efficient step for the removal of residual impurities, mainly high molecular weight proteins, such as vitronectin and inter-alpha inhibitor proteins. In each production step, the active component, pd F IX and contaminating proteins are monitored by biochemical and immunochemical methods and by LC–MS/MS and their removal documented. Our methodology is very helpful for further process optimization, rapid identification of target proteins with relatively low abundance, and for the design of subsequent steps for their removal or purification.     

Electrostatic destabilization of the cytochrome b6f complex in the thylakoid membrane.

Three of the membrane-spanning polypeptides of the chloroplast cytochrome (cyt) b6f complex were sequentially released from the thylakoid membrane, in the order cyt b6, suIV and Rieske iron-sulfur protein, as the pH was increased from 10 to 12, a protocol usually employed to remove peripheral proteins from membranes. The fourth polypeptide of the cyt b6f complex, cyt f, which spans the membrane once, was apparently not released. The pH values for half-release at low ionic strength were approximately 10.7, 11.1 and 11.3 respectively. The separation of the polypeptides of the complex and the sequential release is readily seen at pH 11, where the loss from the membrane of cyt b6, suIV and Fe iron-sulfur center is approximately 90%, 50% and 20%, respectively. the release of cyt b6 from the membrane was reflected by the absence of its characteristic reduced minus oxidized absorbance signal. The pH values at which the release occurred increased as the ionic strength was raised, implying that the release of the b6f polypeptides arises from extrusion due to repulsive electrostatic interactions probably caused by deprotonation of tyrosine and lysine residues. The lipid content of the released polypeptides was very low, consistent with the observation of a non-membranous state. It is proposed that the pH-dependent extrusion requires two electrostatic effects at alkaline pH higher than approximately 10.5: (i) increased electrostatic repulsion between neighbouring polypeptides of the complex, arising from increased net negative charge in the peripheral segments of these polypeptides, which can cause separation of the polypeptides from the complex; and (ii) ionization of residues such as tyrosine in the membrane-spanning alpha-helices, and neutralization of residues such as lysine which can bind to the negative membrane surface.(ABSTRACT TRUNCATED AT 250 WORDS)     

Purification process development of a recombinant monoclonal antibody expressed in glycoengineered Pichia pastoris

A robust and scalable purification process was developed to quickly generate antibody of high purity and sufficient quantity from glycoengineered Pichia pastoris fermentation. Protein A affinity chromatography was used to capture the antibody from fermentation supernatant. A pH gradient elution was applied to the Protein A column to prevent antibody precipitation at low pH. Antibody from Protein A chromatography contained some product related impurities, which were the misassembling of cleaved heavy chain, heavy chain and light chain. It also had some process related impurities, including Protein A residues, endotoxin, host cell DNA and proteins. Cation exchange chromatography with optimal NaCl gradient at pH 4.5-6.0 efficiently removed these product and process related impurities. The antibody from glycoengineered P. pastoris was comparable to its commercial counterpart in heterotetramer folding, physical stability and binding affinity.     

Magnetic cell separation using nano-sized bacterial magnetic particles with reconstructed magnetosome membrane

Magnetic nanoparticles produced by magnetotactic bacterium, bacterial magnetic particles (BacMPs), covered with a lipid bilayer membrane (magnetosome membrane) can be used to separate specific target cells from heterogeneous mixtures because they are easily manipulated by magnets and it is easy to display functional proteins on their surface via genetic engineering. Despite possessing unique and valuable characteristics, the potential toxicity of BacMPs to the separated cells has not been characterized in detail. Here, a novel technique was developed for the reconstruction of magnetosome membrane of BacMPs expressing protein A (protein A-BacMPs) to reduce cytotoxicity and the newly developed nanomaterial was then used for magnetic cell separation. The development of the magnetosome membrane-reconstructed protein A-BacMP was based on the characteristics of the Mms13 anchor protein, which strongly binds to the magnetite surface of BacMPs. Treatment of protein A-BacMPs with detergents removed contaminating proteins but did not affect retention of Mms13-protein A fusion proteins. The particle surfaces were then reconstructed with phosphatidylcholine. The protein A-BacMPs containing reconstructed magnetosome membranes remained dispersible and retained the ability to immobilize antibody. In addition, they contained few membrane surface proteins and endotoxins, which were observed on non-treated protein A-BacMPs. Magnetic separation of monocytes and B-lymphocytes from the peripheral blood was achieved with high purity using magnetosome membrane-reconstructed protein A-BacMPs.     

Salt tolerant membrane adsorbers for robust impurity clearance

Clearance of impurities such as viruses, host cell protein (HCP), and DNA is a critical purification design consideration for manufacture of monoclonal antibody therapeutics. Anion exchange chromatography has frequently been utilized to accomplish this goal; however, anion exchange adsorbents based on the traditional quaternary amine (Q) ligand are sensitive to salt concentration, leading to reduced clearance levels of impurities at moderate salt concentrations (50–150 mM). In this report, membrane adsorbers incorporating four alternative salt tolerant anion exchange ligands were examined for impurity clearance: agmatine, tris‐2‐aminoethyl amine, polyhexamethylene biguanide (PHMB), and polyethyleneimine. Each of these ligands provided greater than 5 log reduction value (LRV) for viral clearance of phage ?X174 (pI ～ 6.7) at pH 7.5 and phage PR772 (pI ～ 4) at pH 4.2 in the presence of salt. Under these same conditions, the commercial Q membrane adsorber provided no clearance (zero LRV). Clearance of host‐cell protein at pH 7.5 was the most challenging test case; only PHMB maintained 1.5 LRV in 150 mM salt. The salt tolerance of PHMB was attributed to its large positive net charge through the presence of multiple biguanide groups that participated in electrostatic and hydrogen bonding interactions with the impurity molecules. On the basis of the results of this study, membrane adsorbers that incorporate salt tolerant anion exchange ligands provide a robust approach to impurity clearance during the purification of monoclonal antibodies. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2009     

In vitro kinetic analysis of the role of the positive charge at the amino-terminal region of signal peptides in translocation of secretory protein across the cytoplasmic membrane in Escherichia coli

By using an in vitro system for the translocation of secretory proteins in Escherichia coli, detailed and quantitative studies were performed as to the function of the positively charged amino acid residues at the amino terminus of the signal peptide. Uncleavable OmpF-Lpp, a model secretory protein carrying an uncleavable signal peptide, and mutant proteins derived from it were used as translocation substrates. When the positive charge, +2 (LysArg) for the wild-type, was changed to 0, -1, or -2, little or no translocation was observed. The number of the positive charge was altered by introducing different numbers of Lys or Arg residues into the amino terminus. The rate of translocation was roughly proportional to this number, irrespective of whether the charged amino acid residues were Lys or Arg. When the amino-terminal LysArg was replaced by His residues, translocation took place more efficiently at pH 6.5 than pH 8.0, whereas that of the wild-type was about the same as the two pH values. We conclude that the signal peptide requires a positive charge at its amino-terminal region to function in the translocation reaction and that the rate of translocation is roughly proportional to the number of the positively charged group, irrespective of the amino acid species that donates the charge. Evidence suggesting that the positive charge is involved in the binding of precursor proteins to the membrane surface to initiate translocation is also presented.     

Purification of human antibodies from transgenic corn using aqueous two‐phase systems

A recombinant human antibody expressed in corn was purified using aqueous two‐phase extraction. The antibody was an immunoglobulin G fully unglycosylated. Using systems of different compositions and/or pHs in each of one or two partitioning stages followed by one more stage in which the antibody was precipitated at the liquid/liquid interface facilitated the removal of different impurities in each stage. The best system yields a product 72% pure (22‐fold purification) with a yield of 49%. The optimum extraction was done in two partitioning stages followed by an interfacial precipitation stage using poly(ethylene)glycol/potassium phosphate systems. NaCl was added to the first stage to eliminate large molecular weight impurities. The pH in the first stage was kept at 6 but a pH of 8 was used in the second stage and in the precipitation stage. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2010     

New method for the selective capture of antibodies under physiolgical conditions

Hydrophobic charge induction chromatography is a recently developed method for protein separation based on the use of dual-mode ligands. They are designed in such a way so as to combine a molecular interaction supported by a mild hydrophobic association effect in the absence of salts. When environmental pH is changed, the ligand becomes ionically charged resulting into the desorption of the protein. This method is applied to the separation of antibodies from ascite fluids and culture supernatants from hybridomas cultured in the presence of fetal bovine serum or in protein free environment. Typically adsorption from cell culture supernatants is accomplished without any pH or ionic strength adjustment; the column is then washed with a typical buffer to eliminate protein impurities. Antibodies are then desorbed using acetate buffer, pH 4. Antibody binding capacity is in the range of 30 mg per ml of resin at 10% breakthrough. Antibody purity varies according to the initial feed stock and can reach values higher than 90% in a single pass. One example of antibody purification process involving hydrophobic charge induction chromatography as a capture step followed by a polishing phase with DEAE Ceramic HyperD is described. Longevity and ligand leakage are compatible with large-scale applications.     

Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry

Assays for identification and quantification of host-cell proteins (HCPs) in biotherapeutic proteins over 5 orders of magnitude in concentration are presented. The HCP assays consist of two types: HCP identification using comprehensive online two-dimensional liquid chromatography coupled with high resolution mass spectrometry (2D-LC/MS), followed by high-throughput HCP quantification by liquid chromatography, multiple reaction monitoring (LC-MRM). The former is described as a “discovery” assay, the latter as a “monitoring” assay. Purified biotherapeutic proteins (e.g., monoclonal antibodies) were digested with trypsin after reduction and alkylation, and the digests were fractionated using reversed-phase (RP) chromatography at high pH (pH 10) by a step gradient in the first dimension, followed by a high-resolution separation at low pH (pH 2.5) in the second dimension. As peptides eluted from the second dimension, a quadrupole time-of-flight mass spectrometer was used to detect the peptides and their fragments simultaneously by alternating the collision cell energy between a low and an elevated energy (MSE methodology). The MSE data was used to identify and quantify the proteins in the mixture using a proven label-free quantification technique (“Hi3” method). The same data set was mined to subsequently develop target peptides and transitions for monitoring the concentration of selected HCPs on a triple quadrupole mass spectrometer in a high-throughput manner (20 min LC-MRM analysis). This analytical methodology was applied to the identification and quantification of low-abundance HCPs in six samples of PTG1, a recombinant chimeric anti-phosphotyrosine monoclonal antibody (mAb). Thirty three HCPs were identified in total from the PTG1 samples among which 21 HCP isoforms were selected for MRM monitoring. The absolute quantification of three selected HCPs was undertaken on two different LC-MRM platforms after spiking isotopically labeled peptides in the samples. Finally, the MRM quantitation results were compared with TOF-based quantification based on the Hi3 peptides, and the TOF and MRM data sets correlated reasonably well. The results show that the assays provide detailed valuable information to understand the relative contributions of purification schemes to the nature and concentrations of HCP impurities in biopharmaceutical samples, and the assays can be used as generic methods for HCP analysis in the biopharmaceutical industry.